New Zealand markets closed
  • NZX 50

    11,065.15
    -37.69 (-0.34%)
     
  • NZD/USD

    0.6539
    +0.0056 (+0.86%)
     
  • NZD/EUR

    0.6090
    +0.0055 (+0.91%)
     
  • ALL ORDS

    7,413.10
    +73.80 (+1.01%)
     
  • ASX 200

    7,182.70
    +76.80 (+1.08%)
     
  • OIL

    114.99
    +0.90 (+0.79%)
     
  • GOLD

    1,857.40
    +3.50 (+0.19%)
     
  • NASDAQ

    12,630.05
    +353.26 (+2.88%)
     
  • FTSE

    7,585.46
    +20.54 (+0.27%)
     
  • Dow Jones

    33,111.89
    +474.70 (+1.45%)
     
  • DAX

    14,462.19
    +230.90 (+1.62%)
     
  • Hang Seng

    20,697.36
    +581.16 (+2.89%)
     
  • NIKKEI 225

    26,781.68
    +176.84 (+0.66%)
     
  • NZD/JPY

    83.0480
    +0.7310 (+0.89%)
     

ResMed Announces Participation in the 40th Annual J.P. Morgan Healthcare Conference

·1-min read

SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, beginning at approximately 1:30 p.m. (Eastern Standard Time) via webcast.

More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. Conference attendees will be able to access the video webcast via the J.P. Morgan Digital Conference Book. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible through February 9, 2022.

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

For investors

For media

Amy Wakeham

Jayme Rubenstein

+1 858.836.5000

+1 858.836.6798

investorrelations@resmed.com

news@resmed.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting